Two peptide receptor ligands 99mTc-EDDA/HYNIC-Tyr 3-octreotide and 99mTc-EDDA/HYNIC-DGlu- octagastrin for scintigraphy of medullary thyroid carcinoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 5, 2007, Pages 613-628

  Kosowicz, Jerzy ^a   Mikołajczak, Renata ^b   Czepczyński, Rafał ^a   Ziemnicka, Katarzyna ^a   Gryczyńska, Maria ^a   Sowiński, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

99mTc EDDA HYNIC TOC; 99mTc EDDA HYNIC DGlu octagastrin; Medullary thyroid carcinoma; Radiopeptide scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CALCITONIN; CHROMOGRANIN A; ETHYLENEDIAMINE N,N' DIACETIC ACID HYDRAZINONICOTINICAMIDE DEXTRO GLUCOSOOCTAGASTRIN TC 99M; ETHYLENEDIAMINE N,N' DIACETIC ACID HYDRAZINONICOTINICAMIDE TYROSYLOCTREOTIDE TC 99M; GASTRIN DERIVATIVE; OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; SUCCIMER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SCINTILLATION CAMERA; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, MEDULLARY; EDETIC ACID; FEMALE; GASTRINS; HUMANS; HYDRAZINES; INDIUM RADIOISOTOPES; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NICOTINIC ACIDS; ORGANOTECHNETIUM COMPOUNDS; RADIONUCLIDE IMAGING; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS;

EID: 35848951172     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.368     Document Type: Article

References (37)

1. Quayle FJ, Moley JF. Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes. J Surg Oncol 2005;89:122.
2. Shoback D, Marcus R, Bikle D, Strewler G; Medullary thyroid carcinoma. In: Greenspan FS, Gardner DG, eds. Basic & Clinical Endocrinology, 6th ed. New York: Lange Medical Books/McGraw-Hill, 2001.
3. Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol 2003;4:339.
4. Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029.
5. Saller B, Moeller L, Gorges R, et al. Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 2002;110:403.
6. Wang Q, Takashima S, Fukuda H, et al. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 2002;125:842.
7. Moll L, McEwan AJ, Shapiro B, et al. Iodine-131 MIBG scintigraphy of neuroendocrine tumours other than phaeochromocytoma and neuroblastoma. J Nucl Med 1987;28:978.
8. 99mTc(V)-dimercaptosuccinic acid (DMSA). Henry Ford Hosp Med J 1989;37:167.
9. 131iodine MIBG in the imaging of medullary thyroid carcinoma. J Nucl Med 1986;27:1150.
10. Behr TM, Gratz S, Markus PM, et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: Are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997;80:2436.
11. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716.
12. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: Results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123.
13. D-Phe1- octreotide. Eur J Nucl Med 2000;27:628.
14. 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318.
15. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biother Radiopharm 2004;19:211.
16. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377.
17. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389.
18. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424.
19. DGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: Preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140.
20. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002;66:399.
21. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424.
22. Nock BA, Maina T, Behe M, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 2005;46:1727.
23. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabelled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects, and limitations. Eur J Nucl Med 1998;25:201.
24. Behe M, Reubi JC, Nock B, et al. Optimisation of In-111 labelled minigastrin related to the kidney uptake. Nucl Med Rev 2005;8:5.
25. Bernard BF, Behe MP, Breeman AP, et al. Preclinical evaluation of minigastrin analogues for CCK-B receptor targeting. Cancer Biother Radiopharm 2003;18:281.
26. 99mTc-labelled minigastrin: comparison of two HYNIC-conjugates in vitro and in vivo. Nucl Med Rev 2005;8:20.
27. 3]-octreotide. Appl Radiat Isot 2006;64:194.
28. 3]-octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368.
29. 3-octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm 1999;14:477.
30. 3-octreotide. Eur J Nucl Med 2001;28:426.
31. 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 2003;30:207.
32. 90Y-labelled somatostatin analog. J Nucl Med 2005;46 (Suppl. 1):13.
33. 99mTc-labelling and in vitro and in vivo evaluation of HYNIC and (Nalpha-His) acetic acid modified [DGlu1]-minigastrin. Bioconjug Chem 2004;15:864.
34. Gotthardt M, Behe MP, Beuter D, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006;33:1273.
35. 111In in comparative evaluation - synthesis, labeling and preliminary biological studies [abstract]. Eur J Nucl Med Mol Imaging 2006;33 (Suppl. 2):S279.
36. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: A clinical study and an analysis of the literature. Nucl Med Commun 2004;25:439.
37. Mirallie E, Vauillez P, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 2005;90:779.